Cytek Biosciences, Inc. (CTKB) fair value analysis
Nasdaq · Updated 2026-10-19
CTKB price how computed
Valuation status
Awaiting full valuationCTKB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $5.25
- Sector
- Healthcare
- 12-month range
- $3.35–$6.09
- Market cap
- $682M
- From 52-week high
- -13.8%
- Shares outstanding
- 130M
- Rank in Healthcare by quality score
- #155 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Cytek Biosciences, Inc. develops and manufactures flow cytometry instruments and reagents used in cell analysis and research applications within the life sciences industry. The company operates globally with a presence in multiple regions including North America, Europe, and Asia-Pacific.
CTKB currently ranks #155 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $682M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $207M
- Net margin
- -39.0%
- EPS (TTM)
- $-0.27
- Gross margin
- 58.9%
- Debt / equity
- 0.08
- Revenue growth (3-yr avg)
- 0.1%
- Shares outstanding
- 130M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 49 · neutral
- 50-day average
- $5.06
- 200-day average
- $4.64
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 3 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-50.0%)
2026-03 ▼ miss (-25.0%)
2025-12 ▬ met (0.0%)
2025-09 ▲ beat (+20.0%)
2025-06 ▬ met (0.0%)
2025-03 ▼ miss (-400.0%)
2024-12 ▲ beat (+9.8%)
2024-09 ▲ beat (+50.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 2 buy · 2 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $5.56
- Target vs last price
- +5.9%
What our data shows for CTKB
- Our model validated 5 trailing price-to-earnings windows for CTKB, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $3.35–$6.09.
- The 14-day relative strength index sits at a neutral 49.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CTKB's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CTKB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for CTKB show a shift in momentum this week, with the RSI zone moving from overbought territory into neutral range. The stock's valuation assessment remains pending full analysis. This change in the RSI zone suggests a moderation in the intensity of recent price movements.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CTKB's derived indicators showed notable shifts this week. The 50/200-day trend state moved from mixed to uptrend, while the RSI zone transitioned from neutral to overbought. The stock's current valuation verdict remains awaiting full valuation.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CTKB stock undervalued?
CTKB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is CTKB's TickrTrends verdict?
CTKB is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does CTKB compare to other Healthcare stocks?
CTKB ranks #155 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CTKB overbought or oversold?
CTKB's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CTKB report earnings next?
CTKB's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does CTKB usually beat earnings estimates?
Over its last 8 reported quarters CTKB beat the consensus estimate 3 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CTKB?
Of 4 analysts covering CTKB, 2 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $5.56 (+5.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.